Josiane Otto

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

Marius Ilié, Élodie Long-Mira, Coraline Bence et al. · Annals of Oncology · 2015 · 584 citations

Medicine, Oncology, Pathology +13

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial

Denis Moro‐Sibilot, Nathalie Cozic, M. Pérol et al. · Annals of Oncology · 2019 · 194 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations

Julien Mazières, Claire Cropet, Laure Montané et al. · Annals of Oncology · 2020 · 189 citations

Pharmacy, Molecular Genetics, Pharmacotherapy +15

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette et al. · Journal of Thoracic Oncology · 2019 · 182 citations · Full text

Medicine, Oncology, Pharmacology +15

Overall survival with crizotinib and next-generation ALK inhibitors in <i>ALK</i>-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

M. Duruisseaux, Benjamin Besse, J. Cadranel et al. · Oncotarget · 2017 · 162 citations · Full text

Medicine, Oncology, Pharmacology +14